Paradromics vs Saluda Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
Paradromics is developing the Connexus fully implantable BCI for speech restoration in paralyzed patients; received FDA IDE approval and completed first human implant at University of Michigan in May 2026;
About
Paradromics is a neurotechnology company based in Austin, Texas, focused on developing brain-computer interface (BCI) technology specifically for restoring communication and independence to patients with severe paralysis caused by ALS, stroke, and spinal cord injury. The company's lead product, the Connexus BCI, is a fully implantable neural interface system designed to record high-resolution neural signals from the motor cortex and decode them into speech output — enabling patients who have lost the ability to speak or move to communicate through their thoughts.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
About
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
AI Visibility Head-to-Head
Key Details
Also Compare
Paradromics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.